9/14/2009

Alcon is in a definitive agreement to acquire ESBATech, a clinical-stage biotech firm in Switzerland, for $150 million in cash and as much as $439 million in milestone dues. The deal would give Alcon access to ESBATech's eye treatment technology and expand its research capability.

Full Story:
Reuters

Related Summaries